Torrent Pharma's US business is set to benefit from new launches and stronger growth momentum, while Germany is likely to see ...

On the operating front, EBITDA for the quarter was reported at ₹964 Crore. It was 9.20% higher than ₹883 in Q4FY24.

Mumbai: Torrent Pharmaceuticals on Wednesday reported a 0.99 per cent quarter-on-quarter (QoQ) decline in its net profit for ...

With the stock's price at Rs 3222.50, Torrent Pharmaceuticals' performance reflects its position in the pharmaceutical sector.

The rally is being fuelled by solid quarterly results and a string of optimistic fiscal 2026 outlooks from leading drugmakers ...

On Wednesday, JPMorgan updated its stance on Torrent Pharma (TRP:IN), revising the company’s price target to INR 3,650 from INR 3,700, while sustaining a Neutral stock rating. The adjustment ...

Torrent Pharmaceuticals Ltd on Tuesday reported an 11 per cent rise in consolidated net profit at Rs 498 crore in the fourth ...

The P/B ratio shows how a stock's market price compares to its book value. It helps gauge whether a stock is undervalued or overvalued relative to its net assets.

Torrent Pharmaceuticals Ltd.'s consolidated net profit surged 11% in the fourth quarter of financial year 2025, according to ...

Torrent Pharmaceuticals is entering a new chapter as Aman Mehta, next-gen scion of the Mehta family, prepares to take over as ...

Torrent Pharmaceuticals Ltd., incorporated in the year 1972, is a Large Cap company (having a market cap of Rs 1,07,446.27 Crore) operating in Pharmaceuticals sector. Torrent Pharmaceuticals Ltd. key ...